{"id":"aop2014","safety":{"commonSideEffects":[{"rate":null,"effect":"Unknown"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"AOP2014 works by binding to the molecular target, which leads to a specific therapeutic effect. This mechanism is still being researched and more information is needed to fully understand its effects.","oneSentence":"AOP2014 is a small molecule that targets the molecular target.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T02:28:38.394Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Phase 2 clinical trials for AOP2014 are currently ongoing for the treatment of various cancers."}]},"trialDetails":[{"nctId":"NCT07468916","phase":"PHASE2","title":"Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2026-03-29","conditions":"Atypical Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic/Myeloproliferative Neoplasm","enrollment":35},{"nctId":"NCT02370329","phase":"PHASE2","title":"P1101 in Treating Patients With Myelofibrosis","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2015-08-12","conditions":"Primary Myelofibrosis, Secondary Myelofibrosis","enrollment":11},{"nctId":"NCT03003325","phase":"PHASE2","title":"The Benefit/Risk Profile of AOP2014 in Low-risk Patients With PV","status":"COMPLETED","sponsor":"FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS","startDate":"2017-02-02","conditions":"Polycythemia Vera","enrollment":127},{"nctId":"NCT03117816","phase":"PHASE3","title":"ENDURE - Efficacy and Safety of AOP2014 With CML Patients in Remission","status":"COMPLETED","sponsor":"Philipps University Marburg","startDate":"2017-05-04","conditions":"Chronic Myeloid Leukemia in Remission","enrollment":214},{"nctId":"NCT02218047","phase":"PHASE3","title":"AOP2014 vs. BAT in Patients With Polycythemia Vera Who Previously Participated in the PROUD-PV Study.","status":"COMPLETED","sponsor":"AOP Orphan Pharmaceuticals AG","startDate":"2014-11","conditions":"Polycythemia Vera","enrollment":170},{"nctId":"NCT01949805","phase":"PHASE3","title":"Pegylated Interferon Alpha-2b Versus Hydroxyurea in Polycythemia Vera","status":"COMPLETED","sponsor":"AOP Orphan Pharmaceuticals AG","startDate":"2013-09","conditions":"Polycythemia Vera","enrollment":257},{"nctId":"NCT02523638","phase":"PHASE3","title":"Study to Assess the Self-administration of AOP2014 Using a Pen, Developed for the Treatment of Polycythemia Vera Patients","status":"COMPLETED","sponsor":"AOP Orphan Pharmaceuticals AG","startDate":"2015-07","conditions":"Polycythemia Vera","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Pegylated-Proline-Interferon α-2b, P1101"],"phase":"phase_2","status":"active","brandName":"AOP2014","genericName":"AOP2014","companyName":"FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS","companyId":"from-fondazione-per-la-ricerca-ospedale-di-bergamo-ets","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AOP2014 is a small molecule that targets the molecular target. Used for Phase 2 clinical trials for AOP2014 are currently ongoing for the treatment of various cancers..","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}